

PRESS RELEASE**Noida, Tuesday, February 03, 2015**

JUBILANT LIFE SCIENCES

The Board of Jubilant Life Sciences Limited, an integrated pharmaceutical and life sciences company met today to approve financial results for the quarter ended December 31, 2014.

Commenting on the Company's performance, Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said:

"We are happy to report that our overall business performance is showing signs of recovery, post the challenges of last six months. Some of the key businesses witnessed healthy profitable growth from the preceding quarter, led by growth in our Radiopharmaceutical business and resumption of operations in CMO business. Our management consolidation of Pharmaceuticals and Life Science Ingredients segments is complete with the appointment of separate CEOs to focus on growth in the respective segments. The acquisition of the minorities stake in Jubilant Cadista will help us in consolidating the US Generics business."

Q3 FY15 Highlights

- Consolidated revenue at Rs. 1,445 Crore
 - Pharmaceuticals revenue at Rs. 701 Crore, contributing 48% to the overall mix
 - LSI revenue at Rs. 744 Crore, contributing 52% to the overall mix
- International revenues at Rs. 1,037 Crore, contributing 72% to the overall mix
- EBITDA at Rs. 191 Crore and margins at 13.2%

9M FY15 Highlights

- Consolidated revenue at Rs. 4,290 Crore
 - Pharmaceuticals revenue at Rs. 1,919 Crore, contributing 45% to the overall mix
 - LSI revenue at Rs. 2,370 Crore, contributing 55% to the overall mix
- International revenues at Rs. 3,042 Crore, contributing 71% to the overall revenues
- EBITDA at Rs. 478 Crore with margins at 11.2%

Pharmaceuticals Segment Review

In Q3 FY2015, Income from Operations of the Pharmaceuticals segment stood at Rs. 701 Crore, contributing 48% to the revenue mix. The segment EBITDA stood at Rs. 140 Crore, with EBITDA margins at 19.9%.



For 9M FY2015, Income from Operations stood at Rs. 1,919 Crore, contributing 45% to the overall revenue mix. The segment EBITDA stood at Rs. 245 crore, with EBITDA margins at 12.7%.

Life Science Ingredients Segment Review

In Q3 FY2015, Income from Operations of the Life Science Ingredients segment stood at Rs. 744 Crore, contributing 52% to the revenue mix. The segment EBITDA stood at Rs 61 Crore, with EBITDA margins at 8.2%.

In 9M FY2015, Income from Operations of the segment stood at Rs 2,370 crore, up 7% YoY and contributing 55% to the revenue mix. The segment EBITDA stood at Rs 256 crore, with EBITDA margins at 10.8%.

Geographical Overview

In Q3 FY2015, revenues from North America stood at Rs. 567 crore, contributing 39% to the overall revenues. Revenues from Europe and Japan stood at Rs. 283 crore, contributing 20% to the revenue mix. Domestic revenues grew 17% YoY at Rs. 409 crore and thus contributing 28% to the overall mix. Revenues in ROW including China stood at Rs. 186 crore, thus contributing 13% to the overall mix.

In 9M FY2015, revenues from North America stood at Rs. 1,570 crore, contributing 37% to the revenue mix. Revenues from Europe and Japan stood at Rs. 891 crore, contributing 21% to the revenue mix. Revenues from ROW including China stood at Rs. 582 crore, contributing 14% to the revenue mix. Domestic revenues stood at Rs. 1,248 crore, up 16% YoY and contributing 29% to the revenue mix.

Outlook

We believe that the segregation of focused business entities will enable our Pharmaceuticals and Life Science Ingredients business to harness their full growth potential going forward. Growth in our Pharmaceuticals segment will be led by our market leadership position in Radiopharmaceuticals, normalization of our CMO business operations and growth in Generics from entry into new markets and launch of new products. Growth in Life Science Ingredients segment is expected from improved performance in our Specialty Ingredients business and expected stabilization of Symtet.



About Jubilant Life Sciences

Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. It also provides services in Contract Manufacturing of Sterile Injectables and Drug Discovery Solutions. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of around 6100 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com

For more information please contact:

For Investors

Ravi Agrawal
Jubilant Life Sciences Limited
Ph: +91-120 436 1002
E-mail: ravi_agrawal@jubl.com

Siddharth Rangnekar
CDR India
Ph: +91 22 6645 1209
E-mail: siddharth@cdr-india.com

Anupam Jain
Jubilant Life Sciences Limited
Ph: +91-120 436 1021
E-mail: anupam_jain@jubl.com

Karl Kolah
CDR India
Ph: +91 22 6645 1220
E-mail: karl@cdr-india.com

For Media

Neha Garg
Jubilant Life Sciences Limited
Ph: +91-120 436 1067
E-mail: neha_garg@jubl.com

Saurabh Gupta
Perfect Relations
Ph: +91 9818075578
E-mail: sgupta@perfectrelations.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.